METHODS
We identified all ODs registered by EMA until September 2011. We also compared the year of registration with the year of patients' access to particular OD. Patients' access to ODs was defined as availability in official Czech distribution chain (wholesalers and/or pharmacies). This availability does not have to necessarily mean that the drug is officially reimbursed. This availability can be implemented by clinical trials, compassionate use or "unofficial" reimbursement per individual patient (under exceptional circumstances on request from physician).
Total expenditures for ODs in particular year were calculated from the databases of State Institute for Drug Control (SUKL). Based on these databases, we can either capture maximum ex-factory prices or the highest possible pharmacy prices (including all margins and VAT), which was our approach. However, within our analysis, we would like to express real expenditures of Health insurance funds on ODs.
We presented the relationship between our calculations of ODs expenditures and total (even OTC) drug expenditures in ex-factory prices. We also presented the relationship between our calculations of ODs expenditures and total drug expenditures by Health insurance funds. The real burden of ODs into Health insurance funds can be either underestimated or overestimated, based on those approaches named above. Since in the first case (underestimation), there are interferences of OTC drugs and also methodology discrepancy (all drugs in ex-factory prices vs. ODs in pharmacy prices). In the second case (overestimation), there must be noted the fact, that ODs are usually not reimbursed up to highest possible pharmacy price. To provide estimation of the real the friction of expenditures of ODs related total drugs budget of Health insurance funds, we present a mean value of both approaches.
RESULTS
Until September 2011, 49 out of 66 EMA registered ODs (74%) have been available in the Czech distribution chain, hence available to Czech patients. The mean duration of period between registration year and year of availability in the Czech distribution chain (among already available ODs) was 2.27 years and median 2 years. This period was longer within past years compared to recent years ( Despite the fact that current availability of ODs to patients (based on our analysis) is relatively good, there has not been a systemic approach how to assess ODs in respect of reimbursement procedure yet. Currently, most ODs are reimbursed on temporary basis in Czech (which can be possibly set up to 3 years); however there is a huge debate how to treat them after this period expiration. It must be noted, that all medicines reimbursed on a standard basis in the Czech Republic must fulfill criteria of being cost-effective under the acceptable threshold of 3 GDP/ capita per QALY gained. 
